Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tregalizumab + MTX in RA (TREAT 2b)
NCT01999192Phase 2Terminated
- Sponsor
- Biotest AG
- Start
- Oct 2013
- Primary completion
- Jul 2015
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of tregalizumab in rheumatoid arthritis (RA) (4 arms), sponsored by Biotest AG. Primary endpoint: American College of Rheumatology 20% Improvement at 12 weeks. Started Oct 2013; status: terminated.
02
Drugs
tregalizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01999192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01999192.